Single-Cell Artificial Intelligence for breakthrough biomedical discovery
The company develops artificial intelligence (AI) software for single-cell data analysis. The underlying algorithms allow them to associate patterns in singlecell data with disease status, similar to how state-of-the-art methods for object recognition associate pixel patterns with objects. They provide a software solution (ScaiVision), wrapping their AI technology for R&D customers from academia, pharmaceutical and clinics. Their product makes it possible to analyse single-cell data that has taken weeks to months before, in days. Using deep learning artificial intelligence, ScaiVision greatly increases interpretation depth, analytical complexity and turn-around time.
News about Scailyte
Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors
Scailyte and Volv Global announce strategic partnership
This partnership helps to accelerate rare disease patient diagnosis
Scailyte closes pre-series A financing round
Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to further advance its biomarker discovery platform.
Scailyte raises CHF 2.75M
Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 2.75M in seed funding and gains Swisscom Ventures